Discontinued — last reported Q3 '21
AbbVie Stock Issuance Proceeds decreased by 23.8% to $48.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 380.0%, from $10.00M to $48.00M.
Higher proceeds typically indicate increased employee participation in equity incentive plans, while lower proceeds may reflect reduced option exercise activity.
Reflects the cash inflows received from the issuance of common stock, primarily driven by employee stock option exercise...
Standard line item for companies with significant equity-based compensation programs for staff and management.
cf_proceeds_from_stock_issuance| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$71.00M | $0.00 | $0.00 | $128.00M | $70.00M | $11.00M | -$209.00M | $65.00M | $48.00M | $36.00M | $31.00M | $127.00M | $10.00M | $67.00M | $10.00M | $56.00M | $5.00M | $63.00M | $48.00M |
| QoQ Change | — | +100.0% | — | — | -45.3% | -84.3% | <-999% | +131.1% | -26.2% | -25.0% | -13.9% | +309.7% | -92.1% | +570.0% | -85.1% | +460.0% | -91.1% | >999% | -23.8% |
| YoY Change | — | — | — | — | +198.6% | — | — | -49.2% | -31.4% | +227.3% | +114.8% | +95.4% | -79.2% | +86.1% | -67.7% | -55.9% | -50.0% | -6.0% | +380.0% |
We use cookies for analytics. See our Privacy and Cookie Policy.